Back to Search Start Over

Perihilar cholangiocarcinoma: Current therapy.

Authors :
Zhang W
Yan LN
Source :
World journal of gastrointestinal pathophysiology [World J Gastrointest Pathophysiol] 2014 Aug 15; Vol. 5 (3), pp. 344-54.
Publication Year :
2014

Abstract

Perihilar cholangiocarcinoma, which is a rare primary malignancy, originates from the epithelial cells of the bile duct. Usually invading the periductal tissues and the lymph nodes, perihilar cholangiocarcinoma is commonly diagnosed in the advanced stage of the disease and has a dismal prognosis. Currently, complete hepatectomy is the primary therapy for curing this disease. Perioperative assessment and available surgical procedures can be considered for achieving a negative margin resection, which is associated with long-term survival and better quality of life. For patients with unresectable cholangiocarcinoma, several palliative treatments have been demonstrated to produce a better outcome; and liver transplantation for selected patients with perihilar cholangiocarcinoma is promising and desirable. However, the role of palliative treatments and liver transplantation was controversial and requires more evidence and substantial validity from multiple institutions. In this article, we summarize the data from multiple institutions and discuss the resectability, mortality, morbidity and outcome with different approaches.

Details

Language :
English
ISSN :
2150-5330
Volume :
5
Issue :
3
Database :
MEDLINE
Journal :
World journal of gastrointestinal pathophysiology
Publication Type :
Academic Journal
Accession number :
25133034
Full Text :
https://doi.org/10.4291/wjgp.v5.i3.344